X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2009) 2009
Newsletter (163) 163
Newspaper Article (118) 118
Publication (36) 36
Book Chapter (30) 30
Magazine Article (5) 5
Dissertation (4) 4
Conference Proceeding (3) 3
Streaming Video (3) 3
Transcript (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ticagrelor (2217) 2217
science & technology (1069) 1069
life sciences & biomedicine (1043) 1043
clopidogrel (987) 987
humans (929) 929
cardiovascular system & cardiology (591) 591
prasugrel (585) 585
adenosine - analogs & derivatives (509) 509
cardiac & cardiovascular systems (497) 497
male (493) 493
female (431) 431
acute coronary syndrome (393) 393
middle aged (386) 386
platelet aggregation inhibitors - therapeutic use (385) 385
cardiac patients (358) 358
aged (355) 355
treatment outcome (336) 336
aspirin (333) 333
coronary heart disease (328) 328
care and treatment (319) 319
research (300) 300
percutaneous coronary intervention (286) 286
ticlopidine - analogs & derivatives (285) 285
acute coronary syndromes (279) 279
platelet aggregation inhibitors - adverse effects (264) 264
pharmacology & pharmacy (254) 254
acute coronary syndrome - drug therapy (252) 252
adenosine - therapeutic use (247) 247
myocardial infarction (243) 243
medical research (241) 241
medicine, experimental (229) 229
cardiology (225) 225
platelet aggregation inhibitors - administration & dosage (221) 221
risk factors (213) 213
purinergic p2y receptor antagonists - therapeutic use (211) 211
analysis (189) 189
heart attacks (188) 188
cardiovascular diseases (185) 185
adenosine - adverse effects (182) 182
ticlopidine - therapeutic use (182) 182
blood platelets (181) 181
drug therapy (181) 181
abridged index medicus (179) 179
adenosine - administration & dosage (178) 178
heart attack (178) 178
transluminal angioplasty (177) 177
patients (157) 157
purinergic p2y receptor antagonists - administration & dosage (155) 155
thrombosis (155) 155
dosage and administration (152) 152
peripheral vascular disease (151) 151
purinergic p2y receptor antagonists - adverse effects (150) 150
clinical trials (147) 147
bleeding (145) 145
hemorrhage - chemically induced (145) 145
blood platelets - drug effects (144) 144
cardiovascular disease (138) 138
mortality (138) 138
stroke (138) 138
time factors (135) 135
cardiovascular (134) 134
hematology (131) 131
physical fitness (131) 131
antiplatelet therapy (127) 127
drug therapy, combination (126) 126
platelet aggregation - drug effects (123) 123
cangrelor (122) 122
prospective studies (120) 120
adult (118) 118
ticagrelor - therapeutic use (118) 118
general & internal medicine (117) 117
platelet aggregation inhibitors - pharmacology (114) 114
prasugrel hydrochloride (114) 114
aspirin - therapeutic use (112) 112
medicine, general & internal (109) 109
coronary artery disease (108) 108
platelets (108) 108
adenosine - pharmacology (102) 102
dual antiplatelet therapy (100) 100
p2y (100) 100
medicine & public health (99) 99
platelet function tests (98) 98
ticagrelor - adverse effects (98) 98
coronary vessels (95) 95
purinergic p2y receptor antagonists - pharmacology (93) 93
stents (91) 91
health aspects (88) 88
ticlopidine - adverse effects (88) 88
adenosine (87) 87
diabetes (87) 87
patient outcomes (87) 87
animals (86) 86
usage (86) 86
blood platelets - metabolism (84) 84
ticlopidine - administration & dosage (84) 84
adenosine - pharmacokinetics (83) 83
ischemia (83) 83
pharmacology (82) 82
ticagrelor - administration & dosage (80) 80
myocardial infarction - drug therapy (79) 79
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2275) 2275
German (30) 30
French (26) 26
Russian (21) 21
Spanish (16) 16
Czech (13) 13
Chinese (6) 6
Turkish (6) 6
Portuguese (5) 5
Korean (4) 4
Italian (3) 3
Japanese (2) 2
Polish (2) 2
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2032 - 2042
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2019, Volume 381, Issue 16, pp. 1524 - 1534
Journal Article
European heart journal, ISSN 1522-9645, 07/2009, Volume 30, Issue 16, pp. 1964 - 1977
Currently, clopidogrel is recommended for treatment of patients with acute coronary syndrome and/or percutaneous coronary intervention. However, the delayed... 
Prasugrel | Clopidogrel | Thienopyridine | Cangrelor | Ticagrelor | Purinoceptor P2Y
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 08/2018, Volume 118, Issue 8, pp. 1409 - 1418
Abstract Morphine delays oral P2Y 12 platelet inhibitor absorption and is associated with adverse outcomes after myocardial infarction. Consequently, many... 
Cellular Haemostasis and Platelets | platelet inhibition | percutaneous coronary intervention | ticagrelor | fentanyl | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Fentanyl - administration & dosage | Fentanyl - adverse effects | Purinergic P2Y Receptor Antagonists - administration & dosage | Humans | Middle Aged | Male | Purinergic P2Y Receptor Antagonists - adverse effects | Percutaneous Coronary Intervention - instrumentation | Ticagrelor - adverse effects | Analgesics, Opioid - adverse effects | Drug Interactions | Time Factors | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Ticagrelor - administration & dosage | Female | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Stents | Platelet Aggregation Inhibitors - adverse effects | Gastrointestinal Absorption - drug effects | Ticagrelor - pharmacokinetics | Administration, Oral | Risk Factors | Purinergic P2Y Receptor Antagonists - pharmacokinetics | Treatment Outcome | Coronary Angiography | Administration, Intravenous | Coronary Artery Disease - diagnostic imaging | Baltimore | Coronary Artery Disease - therapy | Analgesics, Opioid - administration & dosage | Aged | Percutaneous Coronary Intervention - adverse effects
Journal Article
The New England journal of medicine, ISSN 1533-4406, 10/2019, Volume 381, Issue 14, pp. 1309 - 1320
Patients with stable coronary artery disease and diabetes were randomly assigned to receive either ticagrelor plus aspirin or placebo plus aspirin. At 40... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Myocardial Infarction - epidemiology | Follow-Up Studies | Humans | Middle Aged | Hemorrhage - mortality | Male | Incidence | Drug Therapy, Combination - adverse effects | Ticagrelor - adverse effects | Aspirin - adverse effects | Female | Stroke - epidemiology | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor - therapeutic use | Diabetes Mellitus, Type 2 - complications | Platelet Aggregation Inhibitors - adverse effects | Stroke - prevention & control | Double-Blind Method | Hemorrhage - epidemiology | Kaplan-Meier Estimate | Treatment Outcome | Coronary Artery Disease - drug therapy | Coronary Artery Disease - mortality | Coronary Artery Disease - complications | Diabetes Mellitus, Type 2 - mortality | Aged | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Control | Usage | Safety and security measures | Diabetes | Cardiovascular diseases | Drug therapy | Ticagrelor | Coronary heart disease | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Diabetes mellitus | Coronary artery | Cardiovascular disease | Thrombosis | Hemorrhage | Thrombolysis | Bleeding | Design | Ischemia | Blood platelets | Coronary vessels | Population | Diabetes mellitus (non-insulin dependent) | Heart diseases | Research centers | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article
Circulation (New York, N.Y.), ISSN 0009-7322, 11/2019, Volume 140, Issue Suppl_1 Suppl 1, pp. A14779 - A14779
BackgroundPatients with PAD have a high risk of future cardiovascular (CVD) events and mortality. Little is known about the changes in clinical disease stage... 
Ticagrelor | Analysis
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 11/2016, Volume 115, Issue 6, pp. 1079 - 1088
Summary Ticagrelor is an antagonist of the platelet P2Y 12 receptor for ADP, approved for the prevention of thromboembolic events in patients with acute... 
Cellular Haemostasis and Platelets | Megakaryocytes | Platelets | Ticagrelor | P2Y
Journal Article
Revista española de cardiologia, ISSN 0300-8932, 11/2017, Volume 70, Issue 11, pp. 952 - 959
Introduction and objectives The incorporation of the new antiplatelet agents (NAA) prasugrel and ticagrelor into routine clinical practice is irregular and... 
Prasugrel | Propensity score | Registry | Ticagrelor | Real world
Journal Article
Journal Article
Journal Article